PTX-200 and Carboplatin in Ovarian Cancer
NCT01690468
Terminated
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Ovarian Cancer
Register for Updates
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01616303
Completed
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
09/11/2020
Locations: University of Connecticut Health Center, Farmington, Connecticut +1 locations
Conditions: Ovarian Neoplasms
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +648 locations
Conditions: Breast Cancer
Register for Updates
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
NCT00367471
Completed
The purpose of this study is to determine the optimally-tolerated regimens (OTR) for lapatinib in combination with paclitaxel, carboplatin with and without trastuzumab in patients with metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/08/2020
Locations: Novartis Investigative Site, La Jolla, California +2 locations
Conditions: Neoplasms, Breast
Register for Updates
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582
Completed
A randomized, double-blind, 3-arm (1:1:1) study in subjects with first-line Stage IV non-squamous NSCLC. The purpose is to test the efficacy and safety of demcizumab, when given in combination with carboplatin and pemetrexed compared to placebo. The administration of carboplatin and pemetrexed is a standard treatment for patients with non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
09/07/2020
Locations: Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California +44 locations
Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung
Register for Updates
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
NCT01859741
Terminated
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
09/07/2020
Locations: Highlands Oncology Group, Rogers, Arkansas +34 locations
Conditions: Stage IV Small Cell Lung Cancer
Register for Updates
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
NCT00068341
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether docetaxel and carboplatin are more effective with or without trastuzumab in treating breast cancer. PURPOSE: This randomized phase II trial is studying h... Read More
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
08/26/2020
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +3 locations
Conditions: Breast Cancer
Register for Updates
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
NCT00652119
Unknown
The goal of this clinical research study is to learn about the safety and tolerability of paclitaxel and carboplatin when given in combination with Avastin to patients with ovarian, primary peritoneal, or fallopian tube cancer. Objectives: Primary study goals: To investigate the safety and tolerability of carboplatin and paclitaxel administered IP in combination with IV Avastin To determine if Avastin influences the pharmacokinetics of IP administered chemotherapeutic agents Secondary study... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/17/2020
Locations: Johns Hopkins Hospital, Baltimore, Maryland +4 locations
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
NCT00514540
Completed
The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer. The side effects, characteristics of patients who respo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/17/2020
Locations: University of California-San Francisco, San Francisco, California +1 locations
Conditions: Prostate Cancer
Register for Updates
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00049257
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel with carboplatin in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/17/2020
Locations: Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer
NCT00006469
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these treatments before surgery may kill more tumor cells in patients with non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with radiation therapy before surgery in treating patients who have stage IIB non-small cell lung cancer or stage IIIA non-s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/17/2020
Locations: Washington Cancer Institute at Washington Hospital Center, Washington, District of Columbia +1 locations
Conditions: Lung Cancer
Register for Updates
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
NCT02027428
Completed
Maintenance treatment of advanced stage squamous cell NSCLC. Phase III, randomized, open-label, multi-center study of nab-paclitaxel with best supportive care (BSC) or BSC alone as maintenance treatment after response or stable disease (SD) with nab-paclitaxel plus carboplatin as induction in subjects with stage IIIB/IV squamous cell NSCLC. Subjects who discontinued treatment from the maintenance part for any reason other than withdrawal of consent, lost to follow-up, or death, were entered in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2020
Locations: Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama +118 locations
Conditions: Squamous Cell Carcinoma, Non-Small-Cell Lung
Register for Updates